Synapse - Sergio Giralt

Results (38)

Analysis of outcomes in patients (pts) with relapsed/refractory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT)

Meeting Abstract

Pemmaraju, N.; Ravandi, F.; Rondon, G.; Giralt, S.; Chen, J.; Pierce, S.; Champlin, R. E.; De Lima, M.; Qazilbash, M.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

High-dose therapy and posttransplantation symptom burden: Striking a balance

Book Section

Giralt, S. A.; Williams, L. A.
In Cleeland, C. S.; Fisch, M. J.; Dunn, A. J. (Eds.) Cancer Symptom Science: Measurement, Mechanics, and Management (2011)

Fulltext@MSK | Save

Patterns of disease relapse and progression in patients with multiple myeloma after first line therapy with autologous stem cell transplantation: Implications for patient monitoring after transplantation

Meeting Abstract

Zamarin, D.; Bhutani, M.; Chimento, D.; Giralt, S.; Lendvai, N.; Landau, H.; Lesokhin, A.; Chung, D.; Babu, D.; Hassoun, H.
Blood (2011)

Fulltext@MSK | Save

Safety and immunogenicity of the 13-valent protein-conjugated pneumococcal vaccine(PCV13) following related and unrelated hematopoietic stem cell transplantation (HCT)

Meeting Abstract

Small, T. N.; Jakubowski, A. A.; Barker, J. N.; Kernan, N. A.; Prockop, S. E.; Iovino, C. S.; Lestrange, N.; Perales, M. A.; Castro-Malaspina, H.; Koehne, G.; more...
Blood (2011)

Fulltext@MSK | Save

Non-myeloablative allogeneic hematopoietic stem cell transplantation with low-dose total body irradiation and peri-transplant rituximab for B cell non-Hodgkin lymphoma: Favorable disease control in chemosensitive patients

Meeting Abstract

Sauter, C. S.; Papadopoulos, E. B.; Perales, M. A.; Jakubowski, A. A.; Goldberg, J. D.; Koehne, G.; Lechner, L.; Moskowitz, C. H.; Giralt, S.; Barker, J. N.; more...
Blood (2011)

Fulltext@MSK | Save

T-cell depleted (TCD) hematopoietic stem cell (HSC) boosts from the original donor without conditioning for poor graft function (PGF) following allogeneic hematopoietic stem cell transplants (HSCT)

Meeting Abstract

Rosenzweig, M. A.; Kernan, N. A.; Small, T. N.; Maloy, M.; Jakubowski, A. A.; Papadopoulos, E. B.; Perales, M. A.; Boulad, F.; Giralt, S.; Young, J. W.; more...
Blood (2011)

Fulltext@MSK | Save

A randomized phase II trial of fludarabine/melphalan 140 vs fludarabine/melphalan 100 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

Meeting Abstract

Qazilbash, M.; Thall, P. F.; Liu, P.; Orlowski, R. Z.; Bashir, Q.; Shah, N.; Kebriaei, P.; Parmar, S.; Jones, R.; Hosing, C. M.; more...
Blood (2011)

Fulltext@MSK | Save

Graft-versus-host disease (GVHD) after double-unit cord blood transplantation (DCBT) is associated with unique clinical features including a higher incidence of grade III-IV acute GVHD in children

Meeting Abstract

Ponce, D. M.; Gonzales, A. M.; Lubin, M. N.; Castro-Malaspina, H.; Giralt, S. A.; Goldberg, J. D.; Jakubowski, A. A.; Papadopoulos, E. B.; Perales, M. A.; van den Brink, M. R. M.; more...
Blood (2011)

Fulltext@MSK | Save

Phase I/II trial of fludarabine in combination with intravenous busulfan and allogeneic progenitor cell support for patients with high risk hematologic malignancies; Dose matters in reduced intensity regimens